Page last updated: 2024-11-07

5-chloro-8-hydroxy-3,4-dihydro-3-methylisocoumarin-7-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-chloro-8-hydroxy-3,4-dihydro-3-methylisocoumarin-7-carboxylic acid: hydrolysate of ochratoxin A; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID134725
SCHEMBL ID11286588
MeSH IDM0040528

Synonyms (20)

Synonym
1h-2-benzopyran-7-carboxylic acid, 5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-
unii-8eeq4nww8h
5-chloro-8-hydroxy-3,4-dihydro-3-methylisocoumarin-7-carboxylic acid
8eeq4nww8h ,
16281-39-3
5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydroisochromene-7-carboxylic acid
SCHEMBL11286588
5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1h-isochromene-7-carboxylic acid #
5-chloro-8-hydroxy-3-methyl-1-oxoisochroman-7-carboxylic acid
OSFWJKYWJMZKSM-UHFFFAOYSA-N ,
5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1h-2-benzopyran-1-one-7-carboxylic acid
.alpha.-ochratoxin, (+/-)-
5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-carboxylic acid
7-carboxy-5-chloro-8-hydroxy-3,4-dihydro-3-methylisocoumarin
AKOS027447323
7-carboxy-5-chloro-8-hydroxy-3,4-dihydro-3-methyl isocoumarin
5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1h-2-benzopyran-7-carboxylic acid
DTXSID20936751
Q27270258
(+/-)-alpha-ochratoxin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis of curves of plasma level versus time suggests its distribution in two distinct body compartments."( Pharmacokinetics of ochratoxin A in animals.
Galtier, P, 1991
)
0.28

Bioavailability

ExcerptReferenceRelevance
" In conclusion, CHA can reduce OTA concentrations in plasma as well as reducing nephrotoxicity, which may be attributed to a decrease of bioavailability and/or enterohepatic circulation of the toxin."( Dietary cholestyramine reduces ochratoxin A-induced nephrotoxicity in the rat by decreasing plasma levels and enhancing fecal excretion of the toxin.
Barriault, C; Bouchard, G; Frohlich, AA; Kerkadi, A; Marquardt, RR; Tuchweber, B; Yousef, IM, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.85)18.7374
1990's6 (23.08)18.2507
2000's2 (7.69)29.6817
2010's13 (50.00)24.3611
2020's4 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]